Mitosis
Expresscells logo

ExpressCells

Revenue-generating biotech improving research by creating knock-in cell lines with multiple precise genetic insertions faster than competing technologies.

  • Stage Product In Market
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded September 2018
  • Employees 8
  • Incorporation Type C-corp
  • Website xpresscells.com

Company Summary

ExpressCells creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system that creates cell lines up to 75% faster than older technologies and allows multiple knock-ins. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are generating revenue through e-commerce, online promotion, and sales representatives.

Team

  • Matt Handel has over 25 years in life sciences. A graduate of Princeton and MIT, Matt has worked in product development, business development, and commercial roles at both Merck and Shire. He is an experienced fund-raiser, operations lead, and sits on several Boards. This is his third start-up.

  • Fullsizerender
    Founder and Scientific Advisor

    Oscar Perez Leal, MD, has been at Temple University for 15 years, where he conducts research on biochemistry and molecular biology. Oscar is currently a professor in the School of Pharmacy and is an inventor on multiple patents, including ExpressCells’ technology. He has both medical and business degrees.

  • Bef1fe2e a66b 4d38 8611 82bbe44ed11e
    Controller & Financial Advisor

    Connie Davies has a broad background in finance covering many industries. She is Principal of CD Advisory Services, LLC serving startups and development companies in life science. An alumna from Shire, Connie has worked with SaaS and consultancy firms, IT customized technology management, and biotech development companies. She brings a critical eye and optimized approach in business planning and execution.

  • 07898e9c 0be4 4e8e abec 74b379e5ef0a
    Board Director

    Principal, TreD Avon Advisors, LLC. & Interim CEO, SwanBio Therapeutics. Chief Commercial Strategy Officer of Sage Therapeutics, Inc. from 2014 to 2019. Between 2004 and 2014, senior operating (P&L) executive with Shire Pharmaceuticals Group. Prior to that, Tom was with J&J. Between 2000 and 2002, Tom served in C-suite roles as part of Claneil Enterprises, Inc. Earned an MBA from Notre Dame and a BS in civil engineering from Lehigh University.

  • C06c5320 4993 44a0 a686 abda49a5f738
    Senior Scientist

    Joined ExpressCells from the MitoCare Center in the Dept. of Pathology, Anatomy and Cell Biology at Thomas Jefferson University. Experience across the spectrum of molecular biology techniques, including primary and immortalized cell culture; plasmid transfection and RNA interference; gene-editing with CRISPR/Cas9; DNA-RNA isolation, characterization, and cloning; and clone validation. PhD from the University of Graz, Austria.

  • Default avatar
    Wendy DiCicco
    Board Director

    Board Director of EyePoint Pharmaceuticals and Carmell Therapeutics. Previously served on three public and private boards. Previously COO & CFO of Centinel Spine, President & COO of Camber Spine Technologies, and CFO for several medical device and biotechnology companies, including 12 years at Kensey Nash Corporation. Started her career with Deloitte & Touche. B.S. degree in Accounting from Philadelphia College of Textiles and Science.